- Home
- JYNT vs IPHA Comparison
JYNT vs IPHA Comparison
Compare JYNT & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JYNT | IPHA |
|---|---|---|
| Founded | 2010 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 149.5M | 174.2M |
| IPO Year | 2014 | 2019 |
Fundamental Metrics
Financial Performance| Metric | JYNT | IPHA |
|---|---|---|
| Price | $8.86 | $1.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $17.00 | $5.00 |
| AVG Volume (30 Days) | ★ 131.8K | 22.0K |
| Earning Date | 11-06-2025 | 09-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $54,176,002.00 | $14,839,695.00 |
| Revenue This Year | $6.11 | $22.29 |
| Revenue Next Year | $6.13 | $43.90 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 10.47 | N/A |
| 52 Week Low | $7.50 | $1.60 |
| 52 Week High | $13.47 | $2.67 |
Technical Indicators
Market Signals| Indicator | JYNT | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 59.47 | 41.57 |
| Support Level | $8.35 | $1.80 |
| Resistance Level | $9.05 | $1.94 |
| Average True Range (ATR) | 0.27 | 0.07 |
| MACD | 0.05 | -0.00 |
| Stochastic Oscillator | 83.84 | 19.23 |
Price Performance
Historical ComparisonAbout JYNT The Joint Corp.
The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The Company has one operating business segment; The Franchise Operations segment which is comprised of the operating activities of the franchise business unit. The Franchise Operations segment derives revenue from customers by providing access to the Company's franchise license, which represents symbolic intellectual property.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.